|
Session 133
Poster Abstracts
Tenofovir-Associated Renal Dysfunction
Wednesday, 1:30 - 3:30 pm
Poster Hall |
| 777 |
Differences in Calculated Glomerular Filtration Rates in Efavirenz- or Tenofovir-treated Adults in ESS40006
Melanie Thompson*1, R Haubrich2, D Margolis3, S Schneider4, R Schooley2, K Pappa5, J Sail5, L Yau5, and J Hernandez5
1AIDS Res Consortium of Atlanta, GA, US; 2Univ of California, San Diego, US; 3Univ of North Carolina at Chapel Hill, US; 4St Mary Med Ctr Care Clin, Long Beach, CA, US; and 5GlaxoSmithKline, Research Triangle Park, NC, US |
| 778 |
Tenofovir-induced Nephrotoxicity in the First Year of Therapy
Jodie Guest*1,2,3, D Rimland1,2, B Patterson1,4, and K Desilva1
1Atlanta VAMC, Decatur, GA, US; 2Emory Univ Sch of Med, Atlanta, GA, US; 3Rollins Sch of Publ Hlth, Emory Univ, Atlanta, GA, US; and 4Univ of Missouri, Sch of Pharm, Kansas City, US |
| 779 |
Renal Impairment Associated with the Use of Tenofovir
James Heffelfinger*, D Hanson, A Voetsch, A McNaghten, and P Sullivan
CDC, Atlanta, GA, US |
| 780 |
Didanosine and Lower Baseline Body Weight Are Associated with Declining Renal Function among Patients Receiving Tenofovir
Heidi Crane*, R Harrington, S Van Rompaey, and M Kitahata
Univ of Washington, Seattle, US |
781
 |
The Safety of Tenofovir DF for the Treatment of HIV Infection: The First 4 Years
M Nelson1, David Cooper*2, R Schooley3, C Katlama4, J Montaner5, S Curtis6, L Hsu6, B Lu6, S Smith6, J Rooney6, and the Viread Global Expanded Access Prgm
1Chelsea and Westminster Hosp, London, UK; 2Univ of New South Wales, Sydney, Australia; 3Univ of California, San Diego, US; 4Hosp Pitié-Salpétrière, Paris, France; 5Univ of British Columbia, Vancouver, Canada; and 6Gilead Sci, Foster City, CA, US |
|
